Published in Lancet on February 02, 2008
Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ (2009) 4.99
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med (2011) 1.89
Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative. BMJ (2012) 1.78
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation (2009) 1.66
Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia. Ann Thorac Med (2011) 1.56
A multinational study of thromboprophylaxis practice in critically ill children. Crit Care Med (2014) 1.56
Thromboprophylaxis for patients at high risk of VTE. Lancet (2008) 1.40
[Perioperative conversion of oral anticoagulants to heparin (bridging) in ophthalmic medicine]. Ophthalmologe (2010) 1.39
The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int (2016) 1.36
Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts. J Thromb Thrombolysis (2010) 1.26
Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost (2012) 1.12
Procedure-specific venous thromboembolism prophylaxis: a paradigm from colectomy surgery. Surgery (2012) 1.11
HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis (2011) 1.11
Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf (2013) 1.08
Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med (2010) 1.08
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies. PLoS One (2013) 1.08
Venous thromboembolism prophylaxis guideline implementation is improved by nurse directed feedback and audit. Thromb J (2011) 1.01
Current treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol (2010) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Venous thromboembolism risk factor assessment and prophylaxis. Phlebology (2010) 0.92
Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: results from the Indian subset data. Indian J Med Res (2012) 0.91
Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin? J R Soc Med (2013) 0.91
Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases? World J Cardiol (2015) 0.90
Perioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgery. J Am Coll Surg (2011) 0.89
Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist (2012) 0.88
Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis? J Oncol Pract (2009) 0.88
The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 0.87
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis (2011) 0.86
Benefit vs. Risk of a Permanent Inferior Vena Cava Filter in Pulmonary Embolism with Anticoagulation Contraindication. Maedica (Buchar) (2013) 0.86
Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond. Circulation (2009) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer (2009) 0.84
Infection and venous thromboembolism in patients undergoing colorectal surgery: what is the relationship? Dis Colon Rectum (2014) 0.84
Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. Implement Sci (2013) 0.84
ExPeKT--Exploring prevention and knowledge of venous thromboembolism: a two-stage, mixed-method study protocol. BMJ Open (2013) 0.84
Venous thromboembolism prophylaxis in the United States: still room for improvement. J Gen Intern Med (2010) 0.83
Implementing thrombosis guidelines in cancer patients: a review. Rambam Maimonides Med J (2014) 0.83
Predictive accuracy of 29-comorbidity index for in-hospital deaths in US adult hospitalizations with a diagnosis of venous thromboembolism. PLoS One (2013) 0.83
Prevention of venous thromboembolism in medical patients and outpatients. Nat Rev Cardiol (2009) 0.82
The effect of a continuing medical education program on Venous thromboembolism prophylaxis utilization and mortality in a tertiary-care hospital. Thromb J (2014) 0.82
Computer surveillance of patients at high risk for and with venous thromboembolism. AMIA Annu Symp Proc (2010) 0.82
Venous thromboembolism in patients with diabetes mellitus. Am J Med (2012) 0.82
Improving adherence to venous thromoembolism prophylaxis using multiple interventions. Ann Thorac Med (2011) 0.81
Cross-sectional study of adherence to venous thromboembolism prophylaxis guidelines in hospitalized patients. The Trombo-Brit study. Thromb J (2012) 0.81
Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve. Ann Thorac Med (2010) 0.80
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. Support Care Cancer (2012) 0.80
Risk of venous thromboembolism after total hip and knee replacement in older adults with comorbidity and co-occurring comorbidities in the Nationwide Inpatient Sample (2003-2006). BMC Geriatr (2010) 0.80
Cancer and coagulation. Am J Hematol (2012) 0.80
Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis (2010) 0.80
Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example. Med Care (2015) 0.79
Use of provider-level dashboards and pay-for-performance in venous thromboembolism prophylaxis. J Hosp Med (2014) 0.79
Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. Clinics (Sao Paulo) (2016) 0.79
Rate of venous thromboembolism among surgical patients in Australian hospitals: a multicentre retrospective cohort study. BMJ Open (2014) 0.79
Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns. CMAJ (2008) 0.79
A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. BMC Med (2014) 0.79
Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge. Thromb J (2011) 0.79
New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag (2010) 0.79
Implementation of vertical clinical pharmacist service on venous thromboembolism prophylaxis in hospitalized medical patients. Einstein (Sao Paulo) (2014) 0.78
Risk of venous thromboembolic disease and adequacy of prophylaxis in hospitalized patients in Argentina: a multicentric cross-sectional study. Thromb J (2014) 0.78
Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol (2012) 0.78
Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients. HPB (Oxford) (2013) 0.78
Venous thromboembolic events in hospitalised medical patients. Thromb Haemost (2009) 0.78
Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. Gynecol Oncol (2015) 0.78
Fatal pulmonary embolism in hospitalized patients: a large autopsy-based matched case-control study. Clinics (Sao Paulo) (2013) 0.78
The effect of a provider-enhanced clinical decision support tool for guiding venous thromboembolism pharmacoprophylaxis in low-risk patients. Hosp Pract (1995) (2012) 0.78
Clinicians adopting evidence based guidelines: a case study with thromboprophylaxis. BMC Health Serv Res (2011) 0.78
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78
Introducing the patient safety professional: why, what, who, how, and where? J Patient Saf (2011) 0.78
Venous thromboembolism in medical patients during hospitalisation and 3 months after hospitalisation: a prospective observational study. BMJ Open (2016) 0.78
Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer. Oncologist (2012) 0.78
Case-Mix, Care Processes, and Outcomes in Medically-Ill Patients Receiving Mechanical Ventilation in a Low-Resource Setting from Southern India: A Prospective Clinical Case Series. PLoS One (2015) 0.78
Venous thromboembolism prophylaxis in hospitalized patients with pneumonia: a prospective survey. Wien Klin Wochenschr (2009) 0.78
Venous thromboembolism in ENT surgery: a review of the literature and completed audit cycle of adherence to national guidance. Eur Arch Otorhinolaryngol (2013) 0.77
Adherence to local guidelines for venous thromboprophylaxis: a cross-sectional study of medical inpatients in Argentina. Thromb J (2011) 0.77
Venous thromboembolism risk and prophylaxis in the acute hospital care setting: report from the ENDORSE study in Egypt. Thromb J (2012) 0.77
Clustering patterns of comorbidities associated with in-hospital death in hospitalizations of US adults with venous thromboembolism. Int J Med Sci (2013) 0.77
Predicting perioperative venous thromboembolism in Japanese gynecological patients. PLoS One (2014) 0.77
Electronic risk assessment for venous thromboembolism: investigating physicians' rationale for bypassing clinical decision support recommendations. BMJ Open (2014) 0.77
Thromboprophylaxis use in medical and surgical inpatients and the impact of an electronic risk assessment tool as part of a multi-factorial intervention. A report on behalf of the elVis study investigators. J Thromb Thrombolysis (2011) 0.76
New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther (2010) 0.76
Thromboprophylaxis for lung cancer patients--multimodality assessment of clinician practices, perceptions and decision support tools. Support Care Cancer (2014) 0.76
Antithrombotic prophylaxis in the middle East. Mediterr J Hematol Infect Dis (2011) 0.76
Assessing the appropriateness of prevention and management of venous thromboembolism in Australia: a cross-sectional study. BMJ Open (2016) 0.76
A clinical decision support system for venous thromboembolism prophylaxis at a general hospital in a middle-income country. J Bras Pneumol (2013) 0.76
Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009). Thromb Res (2015) 0.75
[Evaluation of venous thromboembolic risk and thromboprophylaxis practice in internal medicine]. Pan Afr Med J (2015) 0.75
Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study. Clinicoecon Outcomes Res (2012) 0.75
Challenges in implementing government-directed VTE guidance for medical patients: a mixed methods study. BMJ Open (2012) 0.75
Hospital out-lying through lack of beds and its impact on care and patient outcome. Scand J Trauma Resusc Emerg Med (2013) 0.75
Risk factors for vascular occlusive events and death due to bleeding in trauma patients; an analysis of the CRASH-2 cohort. PLoS One (2012) 0.75
Variations in risk assessment models may contribute to the existing gap between venous thromboembolism prophylaxis guidelines and adherence. Springerplus (2012) 0.75
Venous thromboembolism prophylaxis in hospitalized elderly patients: Time to consider a 'MUST' strategy. J Geriatr Cardiol (2011) 0.75
Post-traumatic pulmonary embolism in the intensive care unit. Ann Thorac Med (2011) 0.75
Prophylaxis of venous thromboembolism in medical patients: too much or too little? Clin Epidemiol (2012) 0.75
Venous thromboembolism prophylaxis: Solutions are in our hands. Ann Thorac Med (2011) 0.75
Prophylaxis of venous thromboembolism in general surgery: guidelines differ and we still need local policies. Ann R Coll Surg Engl (2011) 0.75
Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000-2011. J Womens Health (Larchmt) (2012) 0.75
The implementation of NICE guidance on venous thromboembolism risk assessment and prophylaxis: a before-after observational study to assess the impact on patient safety across four hospitals in England. BMC Health Serv Res (2013) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Multidetector computed tomography for acute pulmonary embolism. N Engl J Med (2006) 7.57
Mapping human genetic diversity in Asia. Science (2009) 7.40
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
A QTL for rice grain width and weight encodes a previously unknown RING-type E3 ubiquitin ligase. Nat Genet (2007) 5.70
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. Genome Res (2002) 4.69
Genome-wide SNP and haplotype analyses reveal a rich history underlying dog domestication. Nature (2010) 4.64
A rice quantitative trait locus for salt tolerance encodes a sodium transporter. Nat Genet (2005) 4.28
Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med (2010) 4.15
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet (2011) 4.04
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg (2003) 3.91
Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med (2003) 3.90
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. JAMA (2012) 3.52
Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol (2002) 3.45
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med (2007) 3.16
Patterns of care for adults with newly diagnosed malignant glioma. JAMA (2005) 3.08
Genetic evidence supports demic diffusion of Han culture. Nature (2004) 2.92
Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation (2010) 2.76
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Adaptive genic evolution in the Drosophila genomes. Proc Natl Acad Sci U S A (2007) 2.56
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Exploration of gene-gene interaction effects using entropy-based methods. Eur J Hum Genet (2007) 2.42
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation (2004) 2.38
Highly sensitive fluorescent probe for selective detection of Hg2+ in DMF aqueous media. Inorg Chem (2007) 2.38
Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery (2004) 2.38
Genome sequencing and comparative transcriptomics of the model entomopathogenic fungi Metarhizium anisopliae and M. acridum. PLoS Genet (2011) 2.35
Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Analysis of genomic admixture in Uyghur and its implication in mapping strategy. Am J Hum Genet (2008) 2.30
The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem (2010) 2.27
Massive pulmonary embolism. Circulation (2006) 2.27
Perioperative mortality for pancreatectomy: a national perspective. Ann Surg (2007) 2.26
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med (2002) 2.25
Airway management in critical illness. Chest (2007) 2.24
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation (2004) 2.21
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Genetic control of rice plant architecture under domestication. Nat Genet (2008) 2.17
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med (2006) 2.13
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology (2007) 2.09
Upper-extremity deep vein thrombosis. Circulation (2002) 2.09
Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A (2010) 2.07
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother (2005) 2.07
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int (2006) 2.01
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet (2002) 2.00
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97